Dose‐Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting
Authors' conclusion
Taken together, optimised dose-escalation regimens may lead to greater tolerance for nausea and vomiting, which allows to use of higher doses, which are associated with greater therapeutic effectiveness.
Study context
- Population
- Participants exposed to incretin mimetics approved for T2D (GLP-1 RA and the dual GIP/GLP-1 RA tirzepatide) in Phase 1 and Phase 3 trials
- Comparison
- Phase 3 vs Phase 1 trials of incretin mimetics
- Outcome
- Ratio of ED50 (dose eliciting nausea or vomiting in 50% of exposed subjects) Phase 3/Phase 1, as an indicator of developing tolerance
Methodological detailsnon-linear regression dose-response analysis, curve fitting, Phase 1 vs Phase 3 trials
- Non-linear regression dose-response analysis
- Curve fitting
- Phase 1 vs Phase 3 trials
Pooled result
As reported in the abstract
- ED50 ratio significantly higher than 1 for semaglutide (s.c. and oral) and tirzepatide
- Higher ratio (more tolerance) associated with longer escalation period and greater number of dose-escalation steps
Further pooled results
Therapeutic effect sizes (HbA1c and body weight reductions)
- ED50 ratio significantly associated with effect sizes for HbA1c and body weight reductions
Original publication
Dose‐Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting. Diabetes Obes Metab. Published 27 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →